Anders Wennborg

3.5k total citations
51 papers, 2.6k citations indexed

About

Anders Wennborg is a scholar working on Radiology, Nuclear Medicine and Imaging, Molecular Biology and Oncology. According to data from OpenAlex, Anders Wennborg has authored 51 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Radiology, Nuclear Medicine and Imaging, 21 papers in Molecular Biology and 19 papers in Oncology. Recurrent topics in Anders Wennborg's work include Monoclonal and Polyclonal Antibodies Research (26 papers), Radiopharmaceutical Chemistry and Applications (22 papers) and HER2/EGFR in Cancer Research (14 papers). Anders Wennborg is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (26 papers), Radiopharmaceutical Chemistry and Applications (22 papers) and HER2/EGFR in Cancer Research (14 papers). Anders Wennborg collaborates with scholars based in Sweden, United States and Germany. Anders Wennborg's co-authors include Vladimir Tolmachev, Anna Orlova, Joachim Feldwisch, Mattias Sandström, Lars Abrahmsén, Jörgen Carlsson, Fredrik Nilsson, Henrik Lindman, Dan Sandberg and Thuy Tran and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and Cancer Research.

In The Last Decade

Anders Wennborg

51 papers receiving 2.6k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Anders Wennborg 1.7k 1.1k 1.1k 231 190 51 2.6k
J.-P. Mach 1.6k 0.9× 867 0.8× 678 0.6× 481 2.1× 227 1.2× 65 2.4k
Peter Nollau 539 0.3× 1.2k 1.1× 825 0.8× 396 1.7× 156 0.8× 48 2.5k
Marleen Keyaerts 1.9k 1.1× 1.1k 1.0× 1.4k 1.3× 769 3.3× 313 1.6× 70 3.1k
M. Jules Mattes 1.9k 1.1× 1.0k 0.9× 755 0.7× 912 3.9× 308 1.6× 94 3.2k
Russell J. Sanderson 1.0k 0.6× 884 0.8× 1.1k 1.1× 190 0.8× 53 0.3× 18 2.0k
S. V. Litvinov 648 0.4× 1.3k 1.2× 980 0.9× 629 2.7× 234 1.2× 28 2.4k
Rob C. Roovers 2.5k 1.4× 2.6k 2.3× 1.0k 1.0× 1.1k 4.7× 253 1.3× 49 4.2k
S. O. Warnaar 629 0.4× 1.4k 1.3× 971 0.9× 507 2.2× 437 2.3× 51 2.7k
Aya Jakobovits 744 0.4× 1.4k 1.2× 705 0.7× 637 2.8× 411 2.2× 36 2.6k
Amin Hajitou 482 0.3× 1.7k 1.5× 663 0.6× 261 1.1× 181 1.0× 64 3.0k

Countries citing papers authored by Anders Wennborg

Since Specialization
Citations

This map shows the geographic impact of Anders Wennborg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anders Wennborg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anders Wennborg more than expected).

Fields of papers citing papers by Anders Wennborg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anders Wennborg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anders Wennborg. The network helps show where Anders Wennborg may publish in the future.

Co-authorship network of co-authors of Anders Wennborg

This figure shows the co-authorship network connecting the top 25 collaborators of Anders Wennborg. A scholar is included among the top collaborators of Anders Wennborg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anders Wennborg. Anders Wennborg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Feldwisch, Joachim, Lindvi Gudmundsdotter, Elin Gunneriusson, et al.. (2023). Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis. mAbs. 15(1). 2209920–2209920. 35 indexed citations
2.
3.
4.
Sandberg, Dan, Vladimir Tolmachev, Irina Velikyan, et al.. (2017). Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT. European Journal of Nuclear Medicine and Molecular Imaging. 44(8). 1337–1346. 44 indexed citations
5.
Sandström, Mattias, Irina Velikyan, Anders Wennborg, et al.. (2016). Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients. Journal of Nuclear Medicine. 57(6). 867–871. 90 indexed citations
6.
Velikyan, Irina, Anders Wennborg, Joachim Feldwisch, et al.. (2014). GMP compliant preparation of a (68)Gallium-labeled Affibody analogue for breast cancer patient examination : first-in-man. European Journal of Nuclear Medicine and Molecular Imaging. 41. 3 indexed citations
7.
Sørensen, Jens Nørkær, Irina Velikyan, Anders Wennborg, et al.. (2014). Measuring HER2-expression in metastatic breast cancer using 68Ga-ABY025 PET/CT. European Journal of Nuclear Medicine and Molecular Imaging. 41. 3 indexed citations
8.
Sørensen, Jens, Dan Sandberg, Mattias Sandström, et al.. (2014). First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111In-ABY-025 Affibody Molecule. Journal of Nuclear Medicine. 55(5). 730–735. 205 indexed citations
9.
Ahlgren, Sara, Anna Orlova, Helena Wållberg, et al.. (2010). Targeting of HER2-Expressing Tumors Using 111In-ABY-025, a Second-Generation Affibody Molecule with a Fundamentally Reengineered Scaffold. Journal of Nuclear Medicine. 51(7). 1131–1138. 73 indexed citations
10.
Baum, Richard P., Vikas Prasad, Dirk Müller, et al.. (2010). Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules. Journal of Nuclear Medicine. 51(6). 892–897. 241 indexed citations
11.
Tolmachev, Vladimir, et al.. (2010). Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. European Journal of Nuclear Medicine and Molecular Imaging. 38(3). 531–539. 46 indexed citations
12.
Tolmachev, Vladimir, Helena Wållberg, Karl Andersson, et al.. (2009). The influence of Bz-DOTA and CHX-A″-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for 114mIn-mediated targeting therapy. European Journal of Nuclear Medicine and Molecular Imaging. 36(9). 1460–1468. 21 indexed citations
13.
Tran, Thuy, T. Ekblad, Anna Orlova, et al.. (2008). Effects of Lysine-Containing Mercaptoacetyl-Based Chelators on the Biodistribution of 99mTc-Labeled Anti-HER2 Affibody Molecules. Bioconjugate Chemistry. 19(12). 2568–2576. 42 indexed citations
14.
Engfeldt, Torun, Thuy Tran, Anna Orlova, et al.. (2006). Synthesis of technetium-chelating affibody molecules for diagnostic imaging of HER2-expressing tumours. Journal of Peptide Science. 12. 229–229. 1 indexed citations
15.
Tolmachev, Vladimir, Fredrik Nilsson, Charles Widström, et al.. (2006). 111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors.. PubMed. 47(5). 846–53. 85 indexed citations
16.
Orre, Lukas M., Susann Fält, Anna Szeles, et al.. (2006). Rad51-related changes in global gene expression. Biochemical and Biophysical Research Communications. 341(2). 334–342. 7 indexed citations
17.
Fält, Susann, Mats Merup, Gösta Gahrton, Bo Lambert, & Anders Wennborg. (2005). Identification of progression markers in B-CLL by gene expression profiling. Experimental Hematology. 33(8). 883–893. 33 indexed citations
18.
Lindvall, Jessica M., K. Emelie M. Blomberg, Anders Wennborg, & Smith Rjh. (2005). Differential expression and molecular characterisation of Lmo7, Myo1e, Sash1, and Mcoln2 genes in Btk-defective B-cells. Cellular Immunology. 235(1). 46–55. 37 indexed citations
19.
Lambert, Bo, et al.. (1998). Radiation induced chromosomal instability in human T-lymphocytes. Mutation research. Fundamental and molecular mechanisms of mutagenesis. 405(2). 161–170. 26 indexed citations
20.
Åman, Pierre, Tanja Pejović, Anders Wennborg, Sverre Heim, & Felix Mitelman. (1993). Mapping of the 19p13 breakpoint in an ovarian carcinoma between the INSR and TCF3 Loci. Genes Chromosomes and Cancer. 8(2). 134–136. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J.-P. Mach Breakdown of academic impact, for papers by Peter Nollau Breakdown of academic impact, for papers by Marleen Keyaerts Breakdown of academic impact, for papers by M. Jules Mattes Breakdown of academic impact, for papers by Russell J. Sanderson Breakdown of academic impact, for papers by S. V. Litvinov Breakdown of academic impact, for papers by Rob C. Roovers Breakdown of academic impact, for papers by S. O. Warnaar Breakdown of academic impact, for papers by Aya Jakobovits Breakdown of academic impact, for papers by Amin Hajitou
Rankless by CCL
2026